BEIJING, April 18, 2024 /PRNewswire/ — 2024 Beijing International Automotive Exhibition, the largest international auto show this year, is about to open, attracting global attention. As the leading EV brand in China, NETA has officially announced its participation in this exhibition. From 25th April to 4th May, visitors can experience its latest technologies and brand-new product lineup at booth E405 in CIEC (Shunyi Hall, Beijing).

Adhering to the brand value of “Tech for All” and brand mission of “Touchable Smart EV”, NETA Auto is dedicated to provide high-quality smart EVs and advance technology to global users. At the upcoming exhibition, NETA Auto will introduce a brand-new lineup of products. Not only its existing models, NETA X and NETA S, but also unveil the new model, NETA L.
NETA L will debut in both REEV and EV version. It will be delivered to its first Chinese customer at Beijing auto show and will be launched in over 20 countries worldwide during the second half of this year. NETA L will offer an REEV version with an extraordinary combined range of 1070 kilometers. Additionally, NETA L’s most striking feature is its integration with NETA’s all new AI flagship technology – NETA GPT, which will offer global users with a smarter NETA assistant and will redefine the experience of intelligent cockpits.
At this exhibition, NETA Auto will not only showcase its innovative strength and brand-new product lineup of smart EVs, but also seize opportunities to launch series of overseas activities. This move aims to further drive NETA’s global expansion and bring high-quality smart EVs to global customers in vast markets, such as Southeast Asia, the Middle East, and Latin America.
About NETA Auto
NETA Auto, a brand of Hozon New Energy Automobile Co., Ltd., is a leading innovator in the smart EV industry. With a focus on “Tech for All” and “Touchable Smart EV”, NETA develops high-quality EV and cutting-edge technologies. Its lineup includes popular models such as NETA AYA, NETA X, NETA L, NETA GT, and NETA S.
NETA dedicate to bring smart EV to global mass consumer market, introducing new model each year and covering the A0-B segments. NETA has also developed the “Shanhai Platform,” an intelligent and safe car platform, and HOZI Technology, which is committed to develop advanced technologies to meet user demands continuously.
Photo – https://mma.prnewswire.com/media/2390906/NETA_L.jpg

View original content:https://www.prnewswire.co.uk/news-releases/new-product-new-technology-new-strategy-neta-auto-poised-to-shock-2024-beijing-international-automotive-exhibition-302120989.html

Using patient personality traits to pioneer a new era in clinical research.
MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ — Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a significant investment milestone. Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d’Investissement) and WE (Wallonie Entreprendre) have committed strategic investments to drive Cognivia’s mission to “quantify the power of the mind” to optimize and accelerate drug development programs. This infusion of capital will allow Cognivia to deploy its predictive clinical trial solutions that decode the relationship between patient traits and behaviors, thus expediting the development of innovative treatments for patients globally.

Cognivia’s solutions target critical areas that have historically posed significant challenges to drug development, such as the placebo response and medication adherence in clinical trials. Unlike any other, Cognivia is pioneering a quantitative understanding of patients as individuals and integrating these insights into the analysis of clinical trial data and/or optimization of patient engagement strategies. For instance, Placebell™ utilizes predictive algorithms to mitigate the negative impact of the placebo response, enhancing the study power of clinical trials, resulting in increased success rates and reduced clinical trial timelines and costs. Compl-AI predicts the risk of non-compliance and dropout of a patient at screening and during your clinical trial, helping to strengthen and personalize patient engagement strategies.
The capital raised will catalyze Cognivia’s endeavors to introduce its groundbreaking solutions to the market and cement a robust presence in the United States. Through the expansion of its team and the establishment of a subsidiary in the US, Cognivia seeks to foster enhanced commercial and R&D collaborations. In the near future, we plan to fortify our network through strategic alliances, bolstering our advisory board with new members, and building out teams in both the US and EU. This strategic maneuver is in perfect alignment with Cognivia’s steadfast dedication to becoming a leading partner for pharmaceutical and biotechnology companies, empowering them to develop efficacious treatments to address unmet patient needs.
In this latest funding round, Cognivia proudly welcomes the support of three esteemed investors: Vesalius Biocapital IV, a Luxembourg-based venture-capital fund focusing on best-in-class investments in HealthTech and biopharma; SFPIM, the Belgian Sovereign Wealth Fund, providing strategic guidance and financial support for Belgian companies; and WE, contributing to Wallonia’s economic development through financing and support across various sectors.
“We are thrilled to announce Cognivia as the inaugural investment of our fund IV, which focuses on HealthTech and biopharma companies at the forefront of innovation transforming healthcare. We eagerly anticipate partnering with them throughout their commercialization and growth stages.” says Olivier Houben, Partner at Vesalius Biocapital.
“Cognivia’s strategic alliances with Vesalius Biocapital IV, SFPIM and WE signify a pivotal moment in our quest to transform the industry through a unique blend of decades-long industry experience and advanced AI,” remarked Dominique Demolle, CEO/Co-founder of Cognivia. “With this investment and the welcomed addition of new members to our operational team and Company Board and Strategic Advisory Committee, to be announced soon, we are poised to accelerate our efforts in delivering groundbreaking approaches that empower clinicians, researchers and industries to make informed, data-driven decisions, ultimately enhancing outcomes for patients and stakeholders worldwide.”
About Cognivia
Cognivia is the first and only company to combine quantification of patient psychology with artificial intelligence (AI)/machine learning (ML) to improve measurement of therapeutic efficacy in clinical trials – and beyond. Cognivia technologies predict patient behavior and treatment response in clinical trials using predictive ML powered algorithms based on a quantitative understanding of patient psychological traits, expectations and beliefs collected via our own and specific questionnaires developed toward that objective. Cognivia aims at harnessing “the power of the mind” and quantifying this unique phenomenon to improve clinical trial success rates, de-risk drug development and ultimately improve healthcare.
For further details on Cognivia and its groundbreaking AI solutions, please visit cognivia.com or follow @cognivia on LinkedIn.
For media inquiries, please contact: Stephanie AlvarezMarketing Director at [email protected]
Logo – https://mma.prnewswire.com/media/2082754/Cognivia_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cognivia-secures-strategic-15-5m-funding-to-empower-drug-development-with-ai-ml-solutions-302120166.html

IntegrateAI addresses growing market demand for a single, integrated business application that leverages machine learning models in decision management
ROCHELLE PARK, N.J., April 18, 2024 /PRNewswire/ — Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced the launch of IntegrateAI, the newest capability from Sapiens Decision, integrating machine learning models into the business-friendly decision model workbench. 

Sapiens Decision users can integrate machine learning models as another component of their decision model diagram, combining declarative and probabilistic constructs into one consistent and explainable model. Enabling non-technical users to incorporate the machine learning models from data science teams into a single decision model dramatically reduces business and technical complexities, driving greater operational control and efficiency. 
IntegrateAI follows Sapiens Decision’s recent ModelAI release, which brought a Generative AI (GenAI) copilot to decision modelers with integration to Microsoft Azure’s OpenAI Service. The two releases fulfill the initial AI strategy and roadmap of Sapiens Decision to increase the access, speed, and efficacy of decision automation for business users. Sapiens Decision is planning additional AI based products to support the full lifecycle of the decision modeling process, including ExtractAI (for extracting decision logic from legacy code) and OptimizeAI (to optimize business decisions for specific outcomes).
“Sapiens Decision IntegrateAI enables organizations to implement decision automation with greater transparency, explainability, and efficiency by enabling business users to integrate machine learning models within decision models,” said Ilan Buganim, Sapiens CTIO. “Combined with Sapiens Decision’s copilot ModelAI, which leverages GenAI to automatically convert natural language to decision models, enterprises can now turbocharge their application of decision automation for greater business outcomes.” 
Sapiens Decision provides end-to-end decision management capabilities from decision logic extraction from legacy code to decision modeling with no code tools, and deployment through Decision-as-a-Service. Sapiens Decision offers a technology-independent solution to fit any architecture, allowing organizations to reuse their existing infrastructure and governance models. 
Sapiens will be showcasing IntegrateAI at Insurance Innovators USA, Nashville, TN on April 22-23, 2024.
About Sapiens 
Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. With more than 40 years of industry expertise, Sapiens’ cloud-based SaaS insurance platform offers pre-integrated, low-code capabilities across core, data, and digital domains to accelerate our customers’ digital transformation. Serving over 600 customers in more than 30 countries, Sapiens offers insurers across property and casualty, workers’ compensation, and life insurance markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information visit https://sapiens.com or follow us on LinkedIn.
Investor and Media Contact Yaffa Cohen-Ifrah Sapiens Chief Marketing Officer and Head of Investor Relations Email: [email protected] 
Forward Looking Statements
Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to:  the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; the global macroeconomic environment, including headwinds caused by inflation, relatively high interest rates, potentially unfavorable currency exchange rate movements, and uncertain economic conditions, and their impact on our revenues, profitability and cash flows; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the coronavirus epidemic,  and fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.
While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, to be filed in the near future, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.
Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/sapiens-launches-integrateai-the-second-release-in-its-decisionai-portfolio-302120940.html